ATE252151T1 - Apoptosegen von wirbeltieren, zusammensetzungen und verwendungen - Google Patents

Apoptosegen von wirbeltieren, zusammensetzungen und verwendungen

Info

Publication number
ATE252151T1
ATE252151T1 AT94920799T AT94920799T ATE252151T1 AT E252151 T1 ATE252151 T1 AT E252151T1 AT 94920799 T AT94920799 T AT 94920799T AT 94920799 T AT94920799 T AT 94920799T AT E252151 T1 ATE252151 T1 AT E252151T1
Authority
AT
Austria
Prior art keywords
recombinant
compositions
polypeptides
cell death
vertebrate
Prior art date
Application number
AT94920799T
Other languages
English (en)
Inventor
Craig B Thompson
Lawrence H Boise
Gabriel Nunez
Original Assignee
Arch Dev Corp
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Dev Corp, Univ Michigan filed Critical Arch Dev Corp
Application granted granted Critical
Publication of ATE252151T1 publication Critical patent/ATE252151T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT94920799T 1993-06-22 1994-06-22 Apoptosegen von wirbeltieren, zusammensetzungen und verwendungen ATE252151T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/081,448 US5646008A (en) 1993-06-22 1993-06-22 Vertebrate apoptosis gene: compositions and methods
PCT/US1994/007089 WO1995000642A1 (en) 1993-06-22 1994-06-22 Vertebrate apoptosis gene: compositions and methods

Publications (1)

Publication Number Publication Date
ATE252151T1 true ATE252151T1 (de) 2003-11-15

Family

ID=22164231

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94920799T ATE252151T1 (de) 1993-06-22 1994-06-22 Apoptosegen von wirbeltieren, zusammensetzungen und verwendungen

Country Status (8)

Country Link
US (5) US5646008A (de)
EP (1) EP0706568B1 (de)
JP (1) JP3871339B2 (de)
AT (1) ATE252151T1 (de)
AU (1) AU7177394A (de)
CA (1) CA2165969C (de)
DE (1) DE69433240T2 (de)
WO (1) WO1995000642A1 (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001992A (en) * 1999-01-07 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of novel anti-apoptotic bcl-2-related proteins
US5646008A (en) * 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods
US6160106A (en) * 1993-10-12 2000-12-12 Yeda Research & Development Co., Ltd. Tumor suppressor genes, proteins encoded thereby and use of said genes and proteins
WO1995015084A1 (en) 1993-11-30 1995-06-08 Lxr Biotechnology Inc. Novel apoptosis-modulating proteins, dna encoding the proteins and methods of use thereof
US5998131A (en) * 1994-10-07 1999-12-07 Lxr Biotechnology, Inc. Screening methods for the identification of compounds capable of abrogating BaK-BHRF-1 protein interactions
JPH1189573A (ja) * 1994-10-14 1999-04-06 Yutaka Shindo アポトーシス関与遺伝子
US5789389A (en) * 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
WO1996034956A1 (en) * 1995-05-04 1996-11-07 United States Of America, Represented By The Secretary Of The Navy Methods for modulating t cell survival by modulating bcl-xl protein level
US6143291A (en) * 1995-05-04 2000-11-07 Us Navy Methods for modulating T cell survival by modulating bcl-XL protein level
FR2739561B1 (fr) * 1995-10-06 1997-12-26 Inst Nat Sante Rech Med Utilisation d'un vecteur assurant l'expression ou l'augmentation transitoire de l'activite bc1-2
AUPN727595A0 (en) * 1995-12-22 1996-01-18 Walter And Eliza Hall Institute Of Medical Research, The Therapeutic compositions
GB9600660D0 (en) * 1996-01-12 1996-03-13 Ciba Geigy Ag Protein
US5972622A (en) * 1996-02-08 1999-10-26 Desjardins; Louise Method of detecting apoptosis using an anti-human GP46 monoclonal anti-body
AU1873097A (en) * 1996-02-14 1997-09-02 New England Deaconess Hospital Corporation Gene therapy of entothelial cells with anti-apoptotic proteins for transplantation and inflammatory conditions
US5789201A (en) * 1996-02-23 1998-08-04 Cocensys, Inc. Genes coding for bcl-y a bcl-2 homologue
AUPN896596A0 (en) * 1996-03-27 1996-04-26 Walter And Eliza Hall Institute Of Medical Research, The Therapeutic molecules
AU728863B2 (en) * 1996-03-27 2001-01-18 Walter And Eliza Hall Institute Of Medical Research, The A novel mammalian gene, bcl-w, belongs to the bcl-2 family of apoptosis-controlling genes
US5935801A (en) * 1996-03-29 1999-08-10 Dana-Farber Cancer Institute Monoclonal antibody that detects apoptotic antigen
US6472170B1 (en) * 1996-08-02 2002-10-29 Dana-Farber Cancer Institute BCL-Xy, a novel BCL-X isoform, and uses related thereto
US5776905A (en) * 1996-08-08 1998-07-07 The Board Of Trustees Of The Leland Stamford Junior University Apoptotic regression of intimal vascular lesions
US20020194637A1 (en) * 2001-06-06 2002-12-19 University Of Massachussetts Embryonic or stem-like cell lines produced by cross species nuclear transplantation
US7696404B2 (en) * 1996-08-19 2010-04-13 Advanced Cell Technology, Inc. Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions
US5912168A (en) * 1996-08-30 1999-06-15 Genesis Research & Development Corporation Limited CD95 regulatory gene sequences
US7736898B1 (en) 1997-07-11 2010-06-15 Brandeis University Thiaminases and thiaminase genes for use in apoptotic therapies
AU8569698A (en) * 1997-07-11 1999-02-08 Brandeis University Method of inducing apoptosis by reducing the level of thiamin
US6229066B1 (en) 1997-07-30 2001-05-08 The Curators Of The University Of Missouri Cytokinin oxidase
US6172216B1 (en) 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
US6214986B1 (en) * 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression
MXPA01008626A (es) 1999-02-26 2002-04-24 Univ Johns Hopkins Inhibidor novedoso de muerte programada de celula.
JP3907863B2 (ja) * 1999-04-08 2007-04-18 独立行政法人科学技術振興機構 アポトーシス抑制又は促進物質のスクリーニング方法
US6346382B1 (en) 1999-06-01 2002-02-12 Vanderbilt University Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto
US9486429B2 (en) * 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
US6737511B1 (en) * 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
JP4544715B2 (ja) * 1999-08-17 2010-09-15 成男 太田 ラットｂｃｌ−ｘ遺伝子の改変型ｃＤＮＡと改変型タンパク質
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
US6706766B2 (en) * 1999-12-13 2004-03-16 President And Fellows Of Harvard College Small molecules used to increase cell death
JP2003516744A (ja) * 1999-12-14 2003-05-20 ザ バーナム インスティチュート Ｂｃｌ−ｇポリペプチド、それをコードする核酸および使用方法
US7638324B2 (en) 2000-04-06 2009-12-29 Burnham Institute For Medical Research Bcl-G polypeptides, encoding nucleic acids and methods of use
WO2001048014A1 (fr) * 1999-12-27 2001-07-05 Shionogi & Co., Ltd Polypeptides bh4-fusionnes
AU2001231009A1 (en) 2000-01-21 2001-07-31 Beth Israel Deaconess Medical Center Use of pro-apoptotic factors in treatment of atherosclerosis
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
CA2418179A1 (en) * 2000-07-26 2002-01-31 University Of Maryland, Baltimore The protein kinase domain of the large subunit of herpes simplex type 2 ribonucleotide reductase (icp10pk) has anti-apoptopic activity
JP5087201B2 (ja) 2000-08-03 2012-12-05 ジョンズ・ホプキンス・ユニバーシティ 抗原に小胞体シャペロンポリペプチドを連結した分子ワクチン
US20060199780A1 (en) * 2000-11-06 2006-09-07 June Carl H Methods for modulating T cell survival by modulating bcl-XL protein level
US7226992B1 (en) * 2000-11-20 2007-06-05 Abbott Laboratories Mutant Bcl-2 proteins and uses thereof
WO2002053701A2 (en) * 2000-12-29 2002-07-11 Vanderbilt University Epididymal lipocalin gene and uses thereof
FR2826869A1 (fr) * 2001-07-04 2003-01-10 Ct Regional De Lutte Contre Le Produits aptes a traiter les cancers de l'ovaire et a en prevenir les rechutes
US7638326B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
EP2679671B1 (de) 2002-05-24 2019-12-11 Advanced Cell Technology, Inc. Eine Bank von Stammzellen zur Herstellung von Zellen für die Transplantation, die HLA-Antigene hat, die mit denen von Transplantationspatienten passen, und Verfahren zur Herstellung und Verwendung einer solchen Stammzell-Bank
US20060200871A1 (en) * 2002-10-21 2006-09-07 Van Ness Brian G Transgenic non-human animals with expanded mature b cell and plasma cell populations
EP1589969A4 (de) * 2003-01-17 2008-08-13 Merck & Co Inc 3-amino-4-phenylbutansäurederivateals dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes
CA2513684A1 (en) * 2003-01-31 2004-08-19 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2005047501A1 (en) * 2003-02-24 2005-05-26 Johns Hopkins University Molecular vaccines employing nucleic acid encoding anti-apoptotic proteins
US9701725B2 (en) * 2003-05-05 2017-07-11 The Johns Hopkins University Anti-cancer DNA vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
US20050069918A1 (en) * 2003-05-29 2005-03-31 Francois Claret JAB1 as a prognostic marker and a therapeutic target for human cancer
WO2005049073A2 (en) * 2003-11-19 2005-06-02 Survac Aps Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
WO2005078108A2 (en) * 2004-02-09 2005-08-25 The Samuel Roberts Noble Foundation, Inc. Stress resistant plants
WO2005118788A2 (en) 2004-05-27 2005-12-15 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
US20100132058A1 (en) 2004-07-23 2010-05-27 Diatchenko Luda B Methods and materials for determining pain sensitivity and predicting and treating related disorders
CA2594040A1 (en) * 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
CA2595726A1 (en) * 2005-01-26 2006-08-03 The Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin
US20100330105A1 (en) * 2006-08-22 2010-12-30 John Hopkins University Anticancer Combination Therapies
WO2009016433A2 (en) * 2006-09-15 2009-02-05 Ottawa Health Research Institute Oncolytic rhabdovirus
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20080260765A1 (en) * 2007-03-15 2008-10-23 Johns Hopkins University HPV DNA Vaccines and Methods of Use Thereof
CN105861443A (zh) 2007-04-07 2016-08-17 怀特黑德生物医学研究所 体细胞重编程
US7825143B2 (en) 2007-07-10 2010-11-02 Montana State University - Billings Method for controlling the yeast-to-filamentous growth transition in fungi
JP5623916B2 (ja) 2008-01-31 2014-11-12 バンダービルト・ユニバーシティＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ 動脈瘤性くも膜下出血及び血管痙攣に対する医薬組成物
KR20170005155A (ko) * 2008-01-31 2017-01-11 반더빌트유니버시티 폐의 용태에 따른 치료 방법
US20090285861A1 (en) * 2008-04-17 2009-11-19 Tzyy-Choou Wu Tumor cell-based cancer immunotherapeutic compositions and methods
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
KR20230025005A (ko) 2020-06-17 2023-02-21 얀센 바이오테크 인코포레이티드 만능 줄기세포의 제조를 위한 재료 및 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015568A (en) * 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5082774A (en) * 1988-08-30 1992-01-21 The General Hospital Corporation Recombinant human nerve growth factor
JP3454275B2 (ja) * 1992-06-05 2003-10-06 佑 本庶 プログラムされた細胞死に関連した新規なポリペプチドおよびそれをコードするｄｎａ
US5646008A (en) 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods

Also Published As

Publication number Publication date
US5646008A (en) 1997-07-08
JPH09502603A (ja) 1997-03-18
US6911532B2 (en) 2005-06-28
JP3871339B2 (ja) 2007-01-24
US6303331B1 (en) 2001-10-16
US20020137182A1 (en) 2002-09-26
DE69433240T2 (de) 2004-07-15
DE69433240D1 (de) 2003-11-20
EP0706568A1 (de) 1996-04-17
EP0706568B1 (de) 2003-10-15
US6395510B1 (en) 2002-05-28
CA2165969A1 (en) 1995-01-05
US5834309A (en) 1998-11-10
CA2165969C (en) 2010-08-10
AU7177394A (en) 1995-01-17
WO1995000642A1 (en) 1995-01-05

Similar Documents

Publication Publication Date Title
ATE252151T1 (de) Apoptosegen von wirbeltieren, zusammensetzungen und verwendungen
ATE191503T1 (de) Somatostatinrezeptoren
ATE286907T1 (de) Cytokinin-designiertes lerk-5
IL80451A0 (en) Dna sequences,recombinant dna molecules,processes for producing mis-like polypeptides and pharmaceutical containing said peptides
EP1005540A4 (de) Ikk-beta proteines, nukleinsäuren und verfahren
ATE215601T1 (de) Rezeptoren der steroid/thyroid superfamilie von rezeptoren
DK0669929T3 (da) Elk-ligand, et cytokin
SE9004010D0 (sv) Viralt medel
BR9610133A (pt) Vetor recombinante, organismo hospedeiro gram-positivo, processos para engenheirar um organismo hospedeiro gram-positivo, para mostrar a proteìna ou polipeptìdeo desejado em sua superfìcie, para imobilizar organismo hospedeiro gram-positivo e para triar uma coleção de substâncias, vacina, composição e usos de organismos hospedeiro e da composição.
DE69712085D1 (de) Kristallisierbare zusammensetzungen, die einen komplex von protein-domäne ns3aus dem virus von hepatitis c und ns4a enthalten und damit bereitgestellte kristalle
DE69435307D1 (de) Bazillus Thuringiensis und dessen insektizide Proteine
ATE73492T1 (de) Dns die eine sequenz enthalten die fuer ein kristallprotein oder ein polypeptid mit insektiziden eigenschaften kodiert, mit solcher dns transformierte mikroorganismen und zusammensetzungen die diese kristallproteine, polypeptide oder mikroorganismen enthalt.
IL84700A (en) Hybrid proteins,dnas coding therefor,hybrid vectors containing such dnas and hosts transformed therewith,the preparation of such hybrid proteins and pharmaceutical compositions containing them
DE60039677D1 (de) Akt-3 nukleinsäure, polypeptide und deren verwendung
CA2175476A1 (en) Opioid receptor: compositions and methods
NZ504025A (en) Vitamin D receptor related polypeptides (VDRR) and its use in treating inflammatory disease
DE59206628D1 (en) Expression signalpeptid-freier staphylokinasen
Dittmann et al. Characterization of the amino acids essential for the photo-and radioprotective effects of a Bowman–Birk protease inhibitor-derived nonapeptide
AU590861B2 (en) New human lymphotoxin (TNF-beta) polypeptides their prepartion and use
BRPI0409557A (pt) proteìna inibidora recombinante de calicreìna, seqüência de dna, vetor de expressão, célula hospedeira, composição farmacêutica e seu uso, método de produção de proteìna inibidora recombinante de calicreìna e kit de diagnóstico para detecção de calicreìna
IL75553A0 (en) Ache like peptide
ATE213773T1 (de) In apoptosis beteiligte cysteine protease cmh-1 und dns-sequenzen dafür
DE68918399D1 (de) Lymphokine, DNS-Sequenzen, die diese Lymphokine kodieren, und sie enthaltende pharmazeutische Zusammensetzungen.
BR0015170A (pt) Proteìnas de hcv com oxirredução reversìvel e conformação similar à nativa
NO962023L (no) Endotelin-konverterende enzym

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties